UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis

Celltrion

4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that will help the NHS address access inequality.

Celltrion Healthcare calls for the NHS to consider lowering the threshold for starting biologics in patients with rheumatoid arthritis (RA) and to put plans in place to increase patient access to biological treatment.

According to recent findings published in the Annals of the Rheumatic Diseases, disease activity and the use of biological disease-modifying anti-rheumatic drugs among patients with RA vary from country to country, due to different contributing factors, such as per capita GDP, drug affordability and reimbursement policies.

Read Celltrion press release

Michael Wonder

Posted by:

Michael Wonder